Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)

European Urology

Volumn 47, Issue 6, 2005, Pages 824-837

  Rosen, Raymond C ^a   Giuliano, Francois ^b   Carson, Culley C ^c  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b BICÊTRE HOSPITAL   (France)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Benign prostatic hyperplasia; Ejaculatory dysfunction; Erectile dysfunction; Impotence; Lower urinary tract symptoms; Medical therapy; Sexual dysfunction

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1B ADRENERGIC RECEPTOR; CALCIUM CHANNEL BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; SEX HORMONE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ASTHENIA; AUTONOMIC NERVOUS SYSTEM FUNCTION; BINDING AFFINITY; CLINICAL TRIAL; COMORBIDITY; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG SAFETY; EJACULATION; EJACULATION DISORDER; ENDOTHELIUM; ENDOTHELIUM LESION; EPIDEMIOLOGICAL DATA; ERECTILE DYSFUNCTION; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; LOW LEVEL LASER THERAPY; PENIS ERECTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUALITY; SUSTAINED DRUG RELEASE; TRANSURETHRAL RESECTION; URETHRA DISEASE;

HUMANS; MALE; PROSTATIC HYPERPLASIA; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; URINATION DISORDERS;

EID: 19744362189     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2004.12.013     Document Type: Review

References (103)

1. NIH Consensus Conference Impotence. NIH Consensus Development Panel on Impotence JAMA 270 1993 83 90
2. C. McMahon, C. Abdo, and L. Incrocci Disorders of orgasm and ejaculation in men J Sex Med 1 2004 58 65
3. H.A. Feldman, I. Goldstein, D.G. Hatzichristou, R.J. Krane, and J.B. McKinlay Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study J Urol 151 1994 54 61
4. I.A. Ayta, J.B. McKinlay, and R.J. Krane The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences BJU Int 84 1999 50 56
5. M. Braun, G. Wassmer, T. Klotz, B. Reifenrath, M. Mathers, and U. Engelmann Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey' Int J Impot Res 12 2000 305 311
6. R. Rosen, J. Altwein, and P. Boyle Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7) Eur Urol 44 2003 637 649
7. F. Calais Da Silva, P. Marquis, P. Deschaseaux, J.L. Gineste, J. Cauquil, and D.L. Patrick Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study Eur Urol 31 1997 272 280
8. S.J. Berry, D.S. Coffey, P.C. Walsh, and L.L. Ewing The development of human benign prostatic hyperplasia with age J Urol 132 1984 474 479
9. E.O. Laumann, A. Paik, and R.C. Rosen Sexual dysfunction in the United States: prevalence and predictors JAMA 281 1999 537 544
10. A. Martin-Morales, J.J. Sanchez-Cruz, I. Saenz de Tejada, L. Rodriguez-Vela, J.F. Jimenez-Cruz, and R. Burgos-Rodriguez Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study J Urol 166 2001 569 574 discussion 574-5
11. P. Boyle, C. Robertson, and C. Mazzetta The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study BJU Int 92 2003 719 725
12. M.H. Braun, F. Sommer, G. Haupt, M.J. Mathers, B. Reifenrath, and U.H. Engelmann Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical "Aging Male" symptoms? Results of the "Cologne Male Survey" Eur Urol 44 2003 588 594
13. M.H. Blanker, J.L. Bosch, and F.P. Groeneveld Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity Urology 57 2001 763 768
14. M.H. Blanker, A.M. Bohnen, and F.P. Groeneveld Correlates for erectile and ejaculatory dysfunction in older Dutch men: a community-based study J Am Geriatr Soc 49 2001 436 442
15. A. Nicolosi, D.B. Glasser, E.D. Moreira, and M. Villa Prevalence of erectile dysfunction and associated factors among men without concomitant diseases: a population study Int J Impot Res 15 2003 253 257
16. B.L. Hansen Lower urinary tract symptoms (LUTS) and sexual function in both sexes Eur Urol 46 2004 229 234
17. S. Namasivayam, S. Minhas, J. Brooke, A.D. Joyce, S. Prescott, and I. Eardley The evaluation of sexual function in men presenting with symptomatic benign prostatic hyperplasia Br J Urol 82 1998 842 846
18. S.J. Frankel, J.L. Donovan, and T.I. Peters Sexual dysfunction in men with lower urinary tract symptoms J Clin Epidemiol 51 1998 677 685
19. J. Baniel, S. Israilov, J. Shmueli, E. Segenreich, and P.M. Livne Sexual function in 131 patients with benign prostatic hyperplasia before prostatectomy Eur Urol 38 2000 53 58
20. A. Tubaro, M. Polito, L. Giambroni, C. Famulari, E. Gange, and E. Ostardo Sexual function in patients with LUTS suggestive of BPH Eur Urol 40 Suppl. 1 2001 19 22
21. H.H. Leliefeld, H.J. Stoevelaar, and J. McDonnell Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia BJU Int 89 2002 208 213
22. S.T. Brookes, J.L. Donovan, T.J. Peters, P. Abrams, and D.E. Neal Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial BMJ 324 2002 1059 1061
23. G. Vallancien, M. Emberton, N. Harving, and R.J. van Moorselaar Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms J Urol 169 2003 2257 2261
24. K.T. McVary Sexual dysfunction in men with lower urinary tract symptoms and benign prostatic hyperplasia: an emerging link BJU Int 91 2003 770 771
25. E.D. Moreira Jr., C.F. Lbo, A. Diament, A. Nicolosi, and D.B. Glasser Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil Urology 61 2003 431 436
26. S.P. Elliott, M. Gulati, and D.J. Pasta Obstructive lower urinary tract symptoms correlate with erectile dysfunction Urology 63 2004 1148 1152
27. M.A. Khan, M.R. Dashwood, C.S. Thompson, J. Auld, R.J. Morgan, and D.P. Mikhailidis Down-regulation of endothelin-B receptor sites in cavernosal tissue of a rabbit model of partial bladder outlet obstruction: potential clinical relevance World J Urol 17 1999 290 295
28. M.J. Barry, A.T. Cockett, H.L. Holtgrewe, J.D. McConnell, S.A. Sihelnik, and H.N. Winfield Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia J Urol 150 1993 351 358
29. J.L. Bosch, R. Kranse, R. van Mastrigt, and F.H. Schroder Reasons for the weak correlation between prostate volume and urethral resistance parameters in patients with prostatism J Urol 153 1995 689 693
30. K.E. Andersson Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists World J Urol 19 2002 390 396
31. R.R. Kester, U.M. Mooppan, and A.E. Gousse Pharmacological characterization of isolated human prostate J Urol 170 2003 1032 1038
32. A.L. Burnett, M.P. Maguire, and S.L. Chamness Characterization and localization of nitric oxide synthase in the human prostate Urology 45 1995 435 439
33. M. Takeda, R. Tang, E. Shapiro, A.L. Burnett, and H. Lepor Effects of nitric oxide on human and canine prostates Urology 45 1995 440 446
34. K.E. Andersson, and G. Wagner Physiology of penile erection Physiol Rev 75 1995 191 236
35. K.E. Andersson Erectile physiological and pathophysiological pathways involved in erectile dysfunction J Urol 170 2003 S6 S13 discussion S13-4
36. F.R. Kandeel, V.K. Koussa, and R.S. Swerdloff Male sexual function and its disorders: physiology, pathophysiology, clinical investigation, and treatment Endocr Rev 22 2001 342 388
37. K.E. Andersson Pharmacology of penile erection Pharmacol Rev 53 2001 417 450
38. K.J. Hurt, B. Musicki, and M.A. Palese Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection Proc Natl Acad Sci USA 99 2002 4061 4066
39. V.A. Master, and P.J. Turek Ejaculatory physiology and dysfunction Urol Clin North Am 28 2001 363 375
40. M.D. Waldinger The neurobiological approach to premature ejaculation J Urol 168 2002 2359 2367
41. M.D. Waldinger, H.H. Berendsen, B.F. Blok, B. Olivier, and G. Holstege Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system Behav Brain Res 92 1998 111 118
42. D.T. Price, D.A. Schwinn, J.W. Lomasney, L.F. Allen, M.G. Caron, and R.J. Lefkowitz Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate J Urol 150 1993 546 551
43. P.D. Walden, C. Gerardi, and H. Lepor Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate J Urol 161 1999 635 640
44. X.L. Rudner, D.E. Berkowitz, and J.V. Booth Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age Circulation 100 1999 2336 2343
45. B.J. Malloy, D.T. Price, and R.R. Price Alpha1-adrenergic receptor subtypes in human detrusor J Urol 160 1998 937 943
46. J.J. Medina, R.O. Parra, and R.G. Moore Benign prostatic hyperplasia (the aging prostate) Med Clin North Am 83 1999 1213 1229
47. C.M. Reilly, V.S. Stopper, and T.M. Mills Androgens modulate the alpha-adrenergic responsiveness of vascular smooth muscle in the corpus cavernosum J Androl 18 1997 26 31
48. G.J. Christ, B. Stone, and A. Melman Age-dependent alterations in the efficacy of phenylephrine-induced contractions in vascular smooth muscle isolated from the corpus cavernosum of impotent men Can J Physiol Pharmacol 69 1991 909 913
49. G.J. Christ, C.B. Schwartz, and B.A. Stone Kinetic characteristics of alpha 1-adrenergic contractions in human corpus cavernosum smooth muscle Am J Physiol 263 1992 H15 H19
50. N. Wettschureck, and S. Offermanns Rho/Rho-kinase mediated signaling in physiology and pathophysiology J Mol Med 80 2002 629 638
51. R.W. Rees, N.A. Foxwell, D.J. Ralph, P.D. Kell, S. Moncada, and S. Cellek Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells J Urol 170 2003 2517 2522
52. K. Buyukafsar, A. Levent, and M. Ark Expression of Rho-kinase and its functional role in the contractile activity of the mouse vas deferens Br J Pharmacol 140 2003 743 749
53. K. Chitaley, C.J. Wingard, and R. Clinton Webb Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway Nat Med 7 2001 119 122
54. K. Chitaley, T.J. Bivalacqua, and H.C. Champion Adeno-associated viral gene transfer of dominant negative RhoA enhances erectile function in rats Biochem Biophys Res Commun 298 2002 427 432
55. H. Cai, and D.G. Harrison Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress Circ Res 87 2000 840 844
56. M. Barton, F. Cosentino, R.P. Brandes, P. Moreau, S. Shaw, and T.F. Luscher Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin Hypertension 30 1997 817 824
57. J.J. Cho, P. Cadet, E. Salamon, K. Mantione, and G.B. Stefano The nongenomic protective effects of estrogen on the male cardiovascular system: clinical and therapeutic implications in aging men Med Sci Monit 9 2003 RA63 RA68
58. C.A. Haas, A.D. Seftel, K. Razmjouei, M.B. Ganz, N. Hampel, and K. Ferguson Erectile dysfunction in aging: upregulation of endothelial nitric oxide synthase Urology 51 1998 516 522
59. H. Solomon, J.W. Man, and G. Jackson Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator Heart 89 2003 251 253
60. W. Bloch, T. Klotz, C. Loch, G. Schmidt, U. Engelmann, and K. Addicks Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide Prostate 33 1997 1 8
61. A.L. Burnett, D.C. Calvin, and S.L. Chamness Urinary bladder-urethral sphincter dysfunction in mice with targeted disruption of neuronal nitric oxide synthase models idiopathic voiding disorders in humans Nat Med 3 1997 571 574
62. R.A. Mevorach, G.A. Bogaert, and B.A. Kogan Role of nitric oxide in fetal lower urinary tract function J Urol 152 1994 510 514
63. K. Persson, Y. Igawa, A. Mattiasson, and K.E. Andersson Effects of inhibition of the L-arginine/nitric oxide pathway in the rat lower urinary tract in vivo and in vitro Br J Pharmacol 107 1992 178 184
64. M. El-Alfy, V. Luu-The, X.F. Huang, L. Berger, F. Labrie, and G. Pelletier Localization of type 517beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry Endocrinology 140 1999 1481 1491
65. F. Labrie, A. Belanger, L. Cusan, and B. Candas Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology J Clin Endocrinol Metab 82 1997 2403 2409
66. G.G. Kuiper, B. Carlsson, and K. Grandien Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta Endocrinology 138 1997 863 870
67. L. Zakaria, A.G. Anastasiadis, and R. Shabsigh Common conditions of the aging male: erectile dysfunction, benign prostatic hyperplasia, cardiovascular disease and depression Int Urol Nephrol 33 2001 283 292
68. K. Sairam, E. Kulinskaya, T.A. McNicholas, G.B. Boustead, and D.C. Hanbury Sildenafil influences lower urinary tract symptoms BJU Int 90 2002 836 839
69. Mebust WK. Transurethral surgery. In: Walsh P, Retik A, Vaughan ED Jr., Wein A, editors. Campbell's Urology, 7th ed. Philadelphia: WB Saunders Co.; 1998, p. 1453-77.
70. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. AUA Practice Guidelines Committee. J Urol 2003;170:530-47.
71. J.H. Wasson, D.J. Reda, R.C. Bruskewitz, J. Elinson, A.M. Keller, and W.G. Henderson A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate N Engl J Med 332 1995 75 79
72. N. Mottet, F. Bressolle, V. Delmas, M. Robert, and P. Costa Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration Eur Urol 44 2003 101 105
73. K. McKeage, and G.L. Plosker Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia Drugs 62 2002 633 653
74. C.G. Roehrborn, P. Van Kerrebroeck, and J. Nordling Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies BJU Int 92 2003 257 261
75. P. Van Kerrebroeck, A. Jardin, P. van Cangh, and K.U. Laval Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study Eur Urol 41 2002 54 60 discussion 60-1
76. A. Jardin, H. Bensadoun, M.C. Delauche-Cavallier, and P. Attali Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group Lancet 337 1991 1457 1461
77. J.M. Buzelin, M.C. Delauche-Cavallier, S. Roth, C. Geffriaud-Ricouard, and J.P. Santoni Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction Br J Urol 79 1997 898 904 discussion 904-6
78. C.G. Roehrborn Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial Urology 58 2001 953 959
79. R. Van Mooreselaar, M. Emberton, and N. Harving Alf-One Study Group. Alfuzosin 10 mg once daily improves sexual function in men with LUTS and sexual dysfunction [abstract] Urology 169 2003 478 Abstract 1792
80. R.S. Kirby, M. Andersen, P. Gratzke, C. Dahlstrand, and K. Hoye A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia BJU Int 87 2001 192 200
81. A.F. De Rose, G. Carmignani, and C. Corbu Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia Urol Int 68 2002 95 98
82. A.J. Noble, R. Chess-Williams, and C. Couldwell The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha 1D-adrenoceptor subtypes Br J Pharmacol 120 1997 231 238
83. V.L. Pulito, X. Li, and S.S. Varga An investigation of the uroselective properties of four novel alpha(1a)-adrenergic receptor subtype-selective antagonists J Pharmacol Exp Ther 294 2000 224 229
84. P. Abrams, C.C. Schulman, and S. Vaage Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group Br J Urol 76 1995 325 336
85. C.R. Chapple, J.J. Wyndaele, J. Nordling, F. Boeminghaus, A.F. Ypma, and P. Abrams Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group Eur Urol 29 1996 155 167
86. H. Lepor Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group Urology 51 1998 892 900
87. P. Narayan, and A. Tewari A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group J Urol 160 1998 1701 1706
88. Flomax (tamsulosin hydrochloride) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2002.
89. P. Narayan, and H. Lepor Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia Urology 57 2001 466 470
90. F. Giuliano, J. Bernabe, S. Droupy, L. Alexandre, and J. Allard A comparison of the effects of tamsulosin and alfuzosin on neurally evoked increases in bladder neck and seminal vesicle pressure in rats BJU Int 93 2004 605 608
91. T.R. Larson Current treatment options for benign prostatic hyperplasia and their impact on sexual function Urology 61 2003 692 698
92. K.E. Andersson, and M.G. Wyllie Ejaculatory dysfunction: why all alpha-blockers are not equal BJU Int 92 2003 876 877
93. Proscar (finasteride) [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc.; 2004.
94. J.C. Nickel, Y. Fradet, and R.C. Boake Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study CMAJ 155 1996 1251 1259
95. C.G. Roehrborn, P. Boyle, J.C. Nickel, K. Hoefner, and G. Andriole Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia Urology 60 2002 434 441
96. K.H. Park, S.W. Kim, K.D. Kim, and J.S. Paick Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum BJU Int 83 1999 327 333
97. R.C. Rosen, A. Riley, G. Wagner, I.H. Osterloh, J. Kirkpatrick, and A. Mishra The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction Urology 49 1997 822 830
98. M.P. O'Leary, F.J. Fowler, and W.R. Lenderking A brief male sexual function inventory for urology Urology 46 1995 697 706
99. J.L. Donovan, P. Abrams, and T.J. Peters The ICS-'BPH' Study: the psychometric validity and reliability of the ICSmale questionnaire Br J Urol 77 1996 554 562
100. J. Schou, N.R. Holm, and H.H. Meyhoff Sexual function in patients with symptomatic benign prostatic hyperplasia Scand J Urol Nephrol Suppl 179 1996 119 122
101. R.C. Rosen, J.C. Cappelleri, and N. Gendrano III The International Index of Erectile Function (IIEF): a state-of-the-science review Int J Impot Res 14 2002 226 244
102. J. Wincze, R. Rosen, and C. Carson Erection quality scale: initial scale development and validation Urology 64 2004 351 356
103. R. Rosen, J. Catania, L. Pollack, S. Althof, M. O'Leary, and A. Seftel Male Sexual Health Questionnaire (MSHQ): scale development and psychometric validation Urology 64 2004 777 782